logo
  • About
    • The Idea
    • The Concept
    • Strategy
  • Opportunity
    • The Need
    • The Market
    • The Unique Concept
    • The Competition
  • Scientific Foundation
    • Knowledge Platform
    • Modes of Action
    • Results
    • IPR
  • Publications
  • Team
  • News
  • Contact

Month: September 2022

Excellent results from phase I study shows that the BioC gel is safe and well tolerated.

The first part of the phase I study has now been unblinded. The result shows that BioC gel is both safe and well tolerated. There were no adverse events reported and no systemic effect detected.


by Helene Hartman

Recent Posts

  • Xinnate raises SEK 31 million in oversubscribed share issue
  • New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD
  • Xinnate announces successful FDA meeting for TCP-25
  • Xinnate receives Orphan Drug Designation from US FDA for TCP-25
  • Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm

Archives

  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
© 2025 Xinnate. All rights reserved